Open
| Close
| High
| Low
| Previous Close
| Daily Price Gain
|
YTD High
| YTD High Date
| YTD Low
| YTD Low Date
| YTD Price Change
| YTD Gain
|
52 Week High
| 52 Week High Date
| 52 Week Low
| 52 Week Low Date
| 52 Week Price Change
| 52 Week Gain
|
These are sample algorithmic trades based on actual market data.
Stock Symbol
| Exchange
| Company URL
| Company Phone
|
CEO
| Headquarters
| Business Address
| |
Sector
| Industry Category
| Industry Group
| CIK
|
About
OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | |||
Description
OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women worldwide. The company's patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It engages in developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize the fertility treatment consisting of AUGMENT to enhance the energy and health of the woman's eggs by using mitochondria from a woman's EggPC cells; OvaTure to produce mature fertilizable eggs from a woman's own EggPC cells without the need for hormone injections; OvaPrime treatment is used to replenish a woman's egg reserve by transferring the EggPCs from woman's own ovaries; and OvaXon for the prevention of inherited human disease and improvement of animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts. | |||
